Teva Pharmaceuticals Embarks on Strategic Corporate Identity Program to Build a Global Brand

JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced
that it is embarking on a strategic enterprise-wide corporate identity
program to build a global brand. This is the manifestation of the
journey Teva embarked on two years ago, to differentiate itself based on
the unique characteristics of the Company’s business model and create a
new breed of healthcare company.

Teva, the world’s leading producer of medicines, is building on its
strong global footprint, size and scale, to reinforce its focus on
making these medicines more accessible. The company is taking this
opportunity to reaffirm its commitment to placing people at its core to
enable as many as possible to live better, healthier days.

This next phase of Teva’s evolution is signaled by the adoption of a new
brand which is being introduced and embedded within the company over the
next 12 months. The brand embodies a new promise, vision and identity
for Teva and will bring to life the purpose and values the company has
instilled in its employees.

As health care undergoes a period of rapid change, Teva is responding to
the emerging needs of patients by crafting a portfolio of products and
support services that have a place in every aspect of daily life.

“With 64 billion health-related Google searches per year, it is clear
that people increasingly want to take better control of their own health
and wellness, in ways that have not been possible through current
offerings,” said Erez Vigodman, President and CEO of Teva. “As the
provider of a world-class range of both generic and specialty medicines,
and as a company that serves 200 million patients every day, we are in a
unique position to meet the evolving needs of our patients, customers
and the communities we serve and ultimately help enable better outcomes
for health care overall.”

“This project is one part of a comprehensive plan that reflects the
Company’s reinvention to be a strong brand with a unique portfolio of
products and support services, creating best-in-class, sustainable
solutions that help patients manage their overall health,” commented
Iris Beck Codner, Group EVP, Corporate Marketing and Communications. “As
the industry, healthcare systems and people’s involvement in their
health choices continue to evolve, Teva is working to leverage its
unique position to address the emerging needs of patients.”

Teva plans to introduce the new brand to its 43,000 employees around the
world prior to launching the brand externally. “Only when we are
confident that all our employees are aligned around a shared purpose and
how that should be reflected in how we think and how we act, will we be
ready to externalize our new brand,” said Beck Codner.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) is a leading
global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by millions of patients every
day. Headquartered in Israel, Teva is the world’s largest generic
medicines producer, leveraging its portfolio of more than 1,000
molecules to produce a wide range of generic products in nearly every
therapeutic area. In specialty medicines, Teva has a world-leading
position in innovative treatments for disorders of the central nervous
system, including pain, as well as a strong portfolio of respiratory
products. Teva integrates its generics and specialty capabilities in its
global research and development division to create new ways of
addressing unmet patient needs by combining drug development
capabilities with devices, services and technologies. Teva’s net
revenues in 2015 amounted to $19.7 billion. For more information, visit

Teva’s Safe Harbor Statement under the U. S. Private Securities
Litigation Reform Act of 1995:

This release contains forward-looking statements, which are based on
management’s current beliefs and expectations and involve a number of
known and unknown risks and uncertainties that could cause our future
results, performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products;
competition for our specialty products, especially Copaxone® (including
competition from orally-administered alternatives, as well as from
generic equivalents such as the recently launched Sandoz product) and
our ability to continue to migrate users to our 40 mg/mL version and
maintain patients on that version; our ability to identify and
successfully bid for suitable acquisition targets or licensing
opportunities (such as our pending acquisition of Allergan’s generics
business and Rimsa), or to consummate and integrate acquisitions; the
possibility of material fines, penalties and other sanctions and other
adverse consequences arising out of our ongoing FCPA investigations and
related matters; our ability to achieve expected results from the
research and development efforts invested in our pipeline of specialty
and other products; our ability to reduce operating expenses to the
extent and during the timeframe intended by our cost reduction program;
the extent to which any manufacturing or quality control problems damage
our reputation for quality production and require costly remediation;
increased government scrutiny in both the U.S. and Europe of our patent
settlement agreements; our exposure to currency fluctuations and
restrictions as well as credit risks; the effectiveness of our patents,
confidentiality agreements and other measures to protect the
intellectual property rights of our specialty medicines; the effects of
reforms in healthcare regulation and pharmaceutical pricing,
reimbursement and coverage; governmental investigations into sales and
marketing practices, particularly for our specialty pharmaceutical
products; adverse effects of political or economic instability, major
hostilities or acts of terrorism on our significant worldwide
operations; interruptions in our supply chain or problems with internal
or third-party information technology systems that adversely affect our
complex manufacturing processes; significant disruptions of our
information technology systems or breaches of our data security;
competition for our generic products, both from other pharmaceutical
companies and as a result of increased governmental pricing pressures;
competition for our specialty pharmaceutical businesses from companies
with greater resources and capabilities; the impact of continuing
consolidation of our distributors and customers; decreased opportunities
to obtain U.S. market exclusivity for significant new generic products;
potential liability in the U.S., Europe and other markets for sales of
generic products prior to a final resolution of outstanding patent
litigation; our potential exposure to product liability claims that are
not covered by insurance; any failure to recruit or retain key
personnel, or to attract additional executive and managerial talent; any
failures to comply with complex Medicare and Medicaid reporting and
payment obligations; significant impairment charges relating to
intangible assets, goodwill and property, plant and equipment; the
effects of increased leverage and our resulting reliance on access to
the capital markets; potentially significant increases in tax
liabilities; the effect on our overall effective tax rate of the
termination or expiration of governmental programs or tax benefits, or
of a change in our business; variations in patent laws that may
adversely affect our ability to manufacture our products in the most
efficient manner; environmental risks; and other factors that are
discussed in our Annual Report on Form 20-F for the year ended December
31, 2015 and in our other filings with the U.S. Securities and Exchange
Commission (the “SEC”).
Forward-looking statements
speak only as of the date on which they are made and we assume no
obligation to update or revise any forward-looking statements or other
information, whether as a result of new information, future events or


Teva Pharmaceutical Industries Ltd.
United States
C. Mannix
, 215-591-8912
United States
Ran Meir,
Tomer Amitai, 972 (3)
Iris Beck Codner, 972
(3) 926-7687
United States
Denise Bradley,